WO2025104709 - MICRORNA-378A-3P ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/104709
Publication Date
22.05.2025
International Application No.
PCT/IB2024/061444
International Filing Date
16.11.2024
Title **
[English]
MICRORNA-378A-3P ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
[French]
OLIGONUCLÉOTIDES ANTISENS DE MICROARN-378A-3P ET UTILISATIONS ASSOCIÉES
Applicants **
BIORCHESTRA CO., LTD.
Inventors
RYU, Jin-Hyeob
PARK, Young Jin
TAG, Sung Hyun
LIM, Yu Na
KIM, Insun
OH, Seung Yeon
KWON, Mincheol
Priority Data
63/600,279
17.11.2023
US
63/574,745
04.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4537 | |
| EPO | Filing, Examination, Granting | 55657 | |
| Japan | Filing, Examination, Granting | 3801 | |
| South Korea | Filing, Examination, Granting | 3857 | |
| USA | Filing, Examination, Granting | 23790 |
Total:
91,642
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure includes an oligonucleotide comprising a miR-378a-3p inhibitor. The disclosure also includes pharmaceutical compositions comprising the oligonucleotide, and also methods of treating diseases or conditions (i.e., liver diseases or conditions) in a subject in need thereof comprising administering the oligonucleotide to the subject.[French]
La présente divulgation comprend un oligonucléotide comprenant un inhibiteur de miR-378a-3p. La divugation concerne également des compositions pharmaceutiques comprenant l'oligonucléotide, ainsi que des méthodes de traitement de maladies ou de pathologies (c'est-à-dire, des maladies ou des pathologies hépatiques) chez un sujet en ayant besoin, comprenant l'administration de l'oligonucléotide au sujet.